<DOC>
	<DOCNO>NCT01435954</DOCNO>
	<brief_summary>In patient benign prostatic hyperplasia ( BPH ) , combination therapy alpha-blocker ( AB ) 5 alpha-reductase inhibitor ( 5ARI ) show reduce progression acute urinary retention ( AUR ) incidence prostate surgery , also provide symptom relief . The objective study compare likelihood clinical progression ( define AUR and/or prostate-related surgery ) cost BPH patient treat delayed combination therapy BPH patient treat early combination therapy use data United States ( US ) healthcare claim database . The hypothesis study patient prescribe combination therapy early BPH treatment experience well clinical outcome low healthcare cost compare patient treat delayed combination therapy . The null hypothesis difference observe outcome direct medical cost patient treat early combination therapy patient treat delayed combination therapy . The US healthcare claim database include data patient Medicare Advantage well private health plan coverage include Impact health plan . About 14 million people cover set health plan 2007 geographically diverse across US . Data 2000 2009 utilized . The study retrospective cohort analysis .</brief_summary>
	<brief_title>Clinical Progression Costs Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Terazosin</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<criteria>Male Age 50 old index date ( date first fill prescription AB 5ARI enrollment period ) At least one claim ICD9 diagnosis code BPH ( 222.2 600.xx ) position least one pharmacy claim AB ( alfuzosin , doxazosin , tamsulosin , terazosin ) least one fill 5ARI ( dutasteride finasteride ) ( without diagnosis BPH ) Continuous enrollment medical pharmacy benefit 6 month prior index date ( i.e. , baseline period ) 12 month index date ( followup period ) At least one pharmacy claim AB ( alfuzosin , doxazosin , tamsulosin , terazosin ) time preindex period prior index date At least one fill 5ARI ( dutasteride finasteride ) time preindex period prior index date A diagnosis code prostate cancer ( ICD9 = 185 , 198.82 , 233.4 , 236.5 , 239.5 , V10.46 ) bladder cancer ( ICD9 =188 , 198.1 , 223.3 , 233.7 , 239.4 , V10.51 ) position preindex followup period A pharmacy claim finasteride 1 mg tablet ( i.e. , treatment malepattern baldness ) preindex followup period Prostate surgery anytime preindex period 5 month index date</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>benign prostatic hyperplasia</keyword>
	<keyword>surgery</keyword>
	<keyword>5-alpha-reductase inhibitor</keyword>
	<keyword>enlarge prostate</keyword>
	<keyword>acute urinary retention</keyword>
</DOC>